drug prices drug prices

Juanita Milton, who suffers from COPD, uses her nebulizer with albuterol sulfate at her home in Live Oak, Texas. Carolyn Van Houten for Kaiser Health News hide caption

toggle caption
Carolyn Van Houten for Kaiser Health News

Many COPD Patients Struggle To Pay For Each Breath

  • Download
  • <iframe src="https://www.npr.org/player/embed/529759280/531269129" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

An organization campaigning against foreign drug imports has deep connections to the lobbying group PhRMA, which includes Eli Lilly, Pfizer and Bayer. Bill Diodato/Getty Images hide caption

toggle caption
Bill Diodato/Getty Images

Cancer patient John Krahne has delayed taking a prescribed cancer drug because it was too expensive. He walks near his home in Santa Rosa, Calif. Robert Durell for Kaiser Health News hide caption

toggle caption
Robert Durell for Kaiser Health News

Sen. Tom Cotton, R-Ark., is one of three GOP senators seeking an investigation into six-figure annual costs for drugs intended to treat rare diseases. Alex Brandon/AP hide caption

toggle caption
Alex Brandon/AP

State lawmakers in West Virginia say their budget choices are only getting tougher. About a third of state residents are on Medicaid. OZinOH/Flickr hide caption

toggle caption
OZinOH/Flickr

West Virginia Grapples With High Drug Costs

  • Download
  • <iframe src="https://www.npr.org/player/embed/496762064/498091468" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Heather Bresch, CEO of Mylan Pharmacueticals, will face lawmakers' questions Wednesday about the company's steep price hikes for the company's life-saving EpiPen auto-injector. Dale Sparks/AP hide caption

toggle caption
Dale Sparks/AP

Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks

  • Download
  • <iframe src="https://www.npr.org/player/embed/494879607/494914776" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The cost of an EpiPen two-pack has risen more than 400 percent in recent years. The drug is used to halt severe allergic reactions. Joe Raedle/Getty Images hide caption

toggle caption
Joe Raedle/Getty Images

Discounts Aren't Enough to Halt Outrage At High EpiPen Prices

  • Download
  • <iframe src="https://www.npr.org/player/embed/491372193/491390054" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Valeant Pharmaceuticals has been the focus of a congressional investigation into high drug prices. . Michael Nagle/Bloomberg via Getty Images hide caption

toggle caption
Michael Nagle/Bloomberg via Getty Images

The question of how pharmaceutical payments to doctors affect medical practice has been fraught. Hero Images/Getty Images hide caption

toggle caption
Hero Images/Getty Images

Drug-Company Payments Mirror Doctors' Brand-Name Prescribing

  • Download
  • <iframe src="https://www.npr.org/player/embed/470679452/470776709" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Katie Park/NPR

Cancer And Arthritis Drugs Drive Up Spending On Medicines

  • Download
  • <iframe src="https://www.npr.org/player/embed/470417680/470486343" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Erbitux is used to treat cancers that start in the head and neck and tumors there that spread from other parts of the body. Because its effectiveness varies, should the price also? Dr. P. Marazzi/Science Source hide caption

toggle caption
Dr. P. Marazzi/Science Source

Multiple sclerosis pill Tecfidera is on the top 10 list of most costly specialty drugs, as measured by overall spending, for California's health benefit system for public workers and retirees. John/Flickr hide caption

toggle caption
John/Flickr

Martin Shkreli was CEO of Turing Pharmaceuticals when the company boosted the price of a drug by 5,000 percent. He has since resigned. Paul Taggart/Bloomberg via Getty Images hide caption

toggle caption
Paul Taggart/Bloomberg via Getty Images